News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Astellas Pharma Inc. Extends OSI Pharmaceuticals, Inc. Offer, Again
April 23, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- OSI Pharmaceuticals Inc, which has been fending off a hostile takeover bid by Japan's Astellas Pharma Inc, reported much lower first quarter profit on Thursday as results were hit by costs associated with the tender offer.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Astellas Pharma US, Inc.
MORE ON THIS TOPIC
Obesity
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
January 30, 2026
·
2 min read
·
Tristan Manalac
Insights
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
January 29, 2026
·
3 min read
·
Jennifer Smith-Parker
Immunology and inflammation
Lilly Establishes up to $1.9B Repertoire Deal in Second Immune Play of 2026
January 29, 2026
·
2 min read
·
Tristan Manalac
Insights
Biotech’s New Cycle, JPM Deal Hype and Where Alpha Still Hides
January 29, 2026
·
1 min read
·
Jennifer Smith-Parker